{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:57:57Z","timestamp":1793404677759,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["350117"],"award-info":[{"award-number":["350117"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011797","name":"Turun Yliopistollinen Keskussairaala","doi-asserted-by":"publisher","award":["13856"],"award-info":[{"award-number":["13856"]}],"id":[{"id":"10.13039\/501100011797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Sarcoidosis is a multisystem granulomatous disease of unknown etiology, with pulmonary involvement being the most common and clinically significant manifestation. Vascular adhesion protein-1 (VAP-1) plays a key role in leukocyte trafficking to inflamed tissues. [\u2076\u2078Ga]Ga-DOTA-Siglec-9 is a novel PET radiotracer that binds to VAP-1. This proof-of-concept study aimed to evaluate the feasibility of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-Siglec-9 PET\/CT for imaging pulmonary sarcoidosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Six patients with stage 2 pulmonary sarcoidosis (age 50.5\u2009\u00b1\u200913.1 years; bodyweight 84.2\u2009\u00b1\u200914.7\u00a0kg), diagnosed by clinical, radiological, and histological findings, underwent [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-Siglec-9 PET\/CT. Control subjects included six healthy male volunteers (age 37.5\u2009\u00b1\u200910.3 years; bodyweight 80.3\u2009\u00b1\u20093.9\u00a0kg) and one female patient with lung cancer (age 77 years; bodyweight 62\u00a0kg). Tracer uptake was quantified in the lungs, mediastinal lymph nodes, and organs involved in systemic inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with sarcoidosis showed significantly higher [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-Siglec-9 uptake in the lungs (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      1.82\u2009\u00b1\u20090.52 vs. 0.41\u2009\u00b1\u20090.08;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.00006) and mediastinal lymph nodes (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      2.06\u2009\u00b1\u20090.46 vs. 0.89\u2009\u00b1\u20090.26;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0003) compared to healthy controls. Increased uptake was also observed in the liver (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      1.18\u2009\u00b1\u20090.14 vs. 0.80\u2009\u00b1\u20090.10,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0003), spleen (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      1.13\u2009\u00b1\u20090.09 vs. 0.82\u2009\u00b1\u20090.06,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.00003), bone marrow (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      0.30\u2009\u00b1\u20090.12 vs. 0.06\u2009\u00b1\u20090.05,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001), and bone (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      0.27\u2009\u00b1\u20090.11 vs. 0.08\u2009\u00b1\u20090.04,\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u20090.004), indicating systemic inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This proof-of-concept study demonstrates the potential of VAP-1-targeted [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-Siglec-9 PET\/CT for imaging pulmonary sarcoidosis and associated inflammatory activity. Further validation in larger cohorts is warranted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT03755245 (registered 27 November 2018), NCT05212103 (registered 27 January 2022).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-025-03455-8","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:15:59Z","timestamp":1766128559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [68Ga]Ga-DOTA-Siglec-9"],"prefix":"10.1186","volume":"27","author":[{"given":"Prince","family":"Dadson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Yl\u00e4-Outinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kalliokoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Tuokkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Koivum\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Viitanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noora","family":"Rajala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Silvoniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Tolvanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirjo","family":"Nuutila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Saraste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarja","family":"Saaresranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Taimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roivainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"3455_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3390\/jcm9041081","volume":"9","author":"R Jain","year":"2020","unstructured":"Jain R, Yadav D, Puranik N, Guleria R, Jin JO. Sarcoidosis: causes, diagnosis, clinical features, and treatments. J Clin Med. 2020;9:1081.","journal-title":"J Clin Med"},{"key":"3455_CR2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","author":"Statement on sarcoidosis","year":"1999","unstructured":"Statement on sarcoidosis. Joint statement of the American thoracic society (ATS), the European respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"3455_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","volume":"5","author":"J Grunewald","year":"2019","unstructured":"Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR. M\u00fcller-Quernheim J Sarcoidosis Nat Rev Dis Primer. 2019;5:45.","journal-title":"M\u00fcller-Quernheim J Sarcoidosis Nat Rev Dis Primer"},{"key":"3455_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.mayocpiqo.2019.04.006","volume":"3","author":"P Ungprasert","year":"2019","unstructured":"Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019;3:358\u201375.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"3455_CR5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/diagnostics11091558","volume":"11","author":"N Bernardinello","year":"2021","unstructured":"Bernardinello N, Petrarulo S, Balestro E, Cocconcelli E, Veltkamp M, Spagnolo P. Pulmonary sarcoidosis: diagnosis and differential diagnosis. Diagnostics. 2021;11:1558.","journal-title":"Diagnostics"},{"key":"3455_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1055\/s-0034-1376866","volume":"35","author":"H Adams","year":"2014","unstructured":"Adams H, Keijsers RG, Korenromp IH, Grutters JC. FDG PET for gauging of sarcoid disease activity. Semin Respir Crit Care Med. 2014;35:352\u201361.","journal-title":"Semin Respir Crit Care Med"},{"key":"3455_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/jcm9030890","volume":"9","author":"RGM Keijsers","year":"2020","unstructured":"Keijsers RGM, Grutters JC. In which patients with sarcoidosis is FDG PET\/CT indicated? J Clin Med. 2020;9:890.","journal-title":"J Clin Med"},{"key":"3455_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2214\/AJR.07.7001","volume":"190","author":"HB Prabhakar","year":"2008","unstructured":"Prabhakar HB, Rabinowitz CB, Gibbons FK, O\u2019Donnell WJ, Shepard JA, Aquino SL. Imaging features of sarcoidosis on MDCT, FDG PET, and PET\/CT. AJR Am J Roentgenol. 2008;190:S1\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"3455_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/00003072-199811000-00003","volume":"23","author":"SM Bakheet","year":"1998","unstructured":"Bakheet SM, Powe J, Ezzat A, Rostom A. F-18-FDG uptake in tuberculosis. Clin Nucl Med. 1998;23:739\u201342.","journal-title":"Clin Nucl Med"},{"key":"3455_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0002-9440(10)62300-0","volume":"166","author":"M Merinen","year":"2005","unstructured":"Merinen M, Irjala H, Salmi M, Jaakkola I, H\u00e4nninen A, Jalkanen S. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol. 2005;166:793\u2013800.","journal-title":"Am J Pathol"},{"key":"3455_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0002-9440(10)64558-0","volume":"157","author":"K Jaakkola","year":"2000","unstructured":"Jaakkola K, Nikula T, Holopainen R, V\u00e4h\u00e4silta T, Matikainen MT, Laukkanen ML, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol. 2000;157:463\u201371.","journal-title":"Am J Pathol"},{"key":"3455_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1126\/science.1529341","volume":"257","author":"M Salmi","year":"1992","unstructured":"Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science. 1992;257:1407\u20139.","journal-title":"Science"},{"key":"3455_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.4049\/jimmunol.161.3.1549","volume":"161","author":"R Kurkij\u00e4rvi","year":"1998","unstructured":"Kurkij\u00e4rvi R, Adams DH, Leino R, M\u00f6tt\u00f6nen T, Jalkanen S, Salmi M. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol. 1998;161:1549\u201357.","journal-title":"J Immunol"},{"key":"3455_CR14","doi-asserted-by":"publisher","first-page":"22121","DOI":"10.1074\/jbc.M002788200","volume":"275","author":"JQ Zhang","year":"2000","unstructured":"Zhang JQ, Nicoll G, Jones C, Crocker PR. Siglec-9, a novel Sialic acid binding member of the Immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem. 2000;275:22121\u201326.","journal-title":"J Biol Chem"},{"key":"3455_CR15","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2010-09-311076","volume":"118","author":"K Aalto","year":"2011","unstructured":"Aalto K, Autio A, Kiss EA, Elima K, Nymalm Y, Veres TZ, et al. Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. Blood. 2011;118:3725\u201333.","journal-title":"Blood"},{"key":"3455_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11307-023-01885-8","volume":"26","author":"AA Bhowmik","year":"2024","unstructured":"Bhowmik AA, Heikkil\u00e4 TRH, Polari L, Virta J, Liljenb\u00e4ck H, Moisio O, et al. Detection of intestinal inflammation by vascular adhesion protein-1-targeted [68Ga]Ga-DOTA-Siglec-9 positron emission tomography in murine models of inflammatory bowel disease. Mol Imaging Biol. 2024;26:322\u201333.","journal-title":"Mol Imaging Biol"},{"key":"3455_CR17","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1007\/s12350-023-03371-8","volume":"30","author":"A Jahandideh","year":"2023","unstructured":"Jahandideh A, Virta J, Li XG, Liljenb\u00e4ck H, Moisio O, Ponkamo J, et al. Vascular adhesion protein-1-targeted PET imaging in autoimmune myocarditis. J Nucl Cardiol. 2023;30:2760\u201372.","journal-title":"J Nucl Cardiol"},{"key":"3455_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13075-017-1460-4","volume":"19","author":"R Siitonen","year":"2017","unstructured":"Siitonen R, Pietik\u00e4inen A, Liljenb\u00e4ck H, K\u00e4kel\u00e4 M, S\u00f6derstr\u00f6m M, Jalkanen S, et al. Targeting of vascular adhesion protein-1 by positron emission tomography visualizes sites of inflammation in borrelia burgdorferi-infected mice. Arthritis Res Ther. 2017;19:254.","journal-title":"Arthritis Res Ther"},{"key":"3455_CR19","doi-asserted-by":"publisher","first-page":"35089","DOI":"10.1038\/srep35089","volume":"6","author":"JMU Silvola","year":"2016","unstructured":"Silvola JMU, Virtanen H, Siitonen R, Hellberg S, Liljenb\u00e4ck H, Mets\u00e4l\u00e4 O, et al. Leukocyte trafficking-associated vascular adhesion protein 1 is expressed and functionally active in atherosclerotic plaques. Sci Rep. 2016;6:35089.","journal-title":"Sci Rep"},{"key":"3455_CR20","first-page":"18","volume":"6","author":"J Retamal","year":"2016","unstructured":"Retamal J, S\u00f6rensen J, Lubberink M, Suarez-Sipmann F, Batista Borges J, Feinstein R, et al. Feasibility of 68Ga-labeled Siglec-9 peptide for the imaging of acute lung inflammation: a pilot study in a Porcine model of acute respiratory distress syndrome. Am J Nucl Med Mol Imaging. 2016;6:18\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"3455_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2967\/jnumed.120.250696","volume":"62","author":"R Viitanen","year":"2021","unstructured":"Viitanen R, Moisio O, Lankinen P, Li X-G, Koivum\u00e4ki M, Suilamo S, et al. First-in-humans study of 68Ga-DOTA-Siglec-9, a PET ligand targeting vascular adhesion protein 1. J Nucl Med. 2021;62:577\u201383.","journal-title":"J Nucl Med"},{"key":"3455_CR22","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1039\/C7RA12423F","volume":"8","author":"M K\u00e4kel\u00e4","year":"2018","unstructured":"K\u00e4kel\u00e4 M, Luoto P, Viljanen T, Virtanen H, Liljenb\u00e4ck H, Jalkanen S, et al. Adventures in radiosynthesis of clinical grade [68Ga]Ga-DOTA-Siglec-9. RSC Adv. 2018;8:8051\u20136.","journal-title":"RSC Adv"},{"key":"3455_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2967\/jnmt.112.112649","volume":"41","author":"JZ Long","year":"2013","unstructured":"Long JZ, Jacobson MS, Hung JC. Comparison of fastlab 18F-FDG production using phosphate and citrate buffer cassettes. J Nucl Med Technol. 2013;41:32\u20134.","journal-title":"J Nucl Med Technol"},{"key":"3455_CR24","unstructured":"Addendum 1 to ICRP Publication 128: Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances [Ann. ICRP 44(2S), 2015]. Ann ICRP. 2020;146645320936035.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/32663069\/ ."},{"key":"3455_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCGENETICS.113.000543","volume":"7","author":"K Aalto","year":"2014","unstructured":"Aalto K, Havulinna AS, Jalkanen S, Salomaa V, Salmi M. Soluble vascular adhesion protein-1 predicts incident major adverse cardiovascular events and improves reclassification in a Finnish prospective cohort study. Circ Cardiovasc Genet. 2014;7:529\u201335.","journal-title":"Circ Cardiovasc Genet"},{"key":"3455_CR26","doi-asserted-by":"publisher","first-page":"170012","DOI":"10.1183\/16000617.0012-2017","volume":"26","author":"S Ohshimo","year":"2017","unstructured":"Ohshimo S, Guzman J, Costabel U, Bonella F. Differential diagnosis of granulomatous lung disease: clues and pitfalls. Eur Respir Rev. 2017;26:170012.","journal-title":"Eur Respir Rev"},{"key":"3455_CR27","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","volume":"201","author":"ED Crouser","year":"2020","unstructured":"Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and detection of Sarcoidosis. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:e26\u201351.","journal-title":"Am J Respir Crit Care Med"},{"key":"3455_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/cells11010059","volume":"11","author":"C Tana","year":"2021","unstructured":"Tana C, Donatiello I, Caputo A, Tana M, Naccarelli T, Mantini C, et al. Clinical features, histopathology and differential diagnosis of sarcoidosis. Cells. 2021;11:59.","journal-title":"Cells"},{"key":"3455_CR29","first-page":"1551","volume":"42","author":"T Mochizuki","year":"2001","unstructured":"Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551\u20135.","journal-title":"J Nucl Med"},{"key":"3455_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/MCP.0b013e3283645950","volume":"19","author":"D Israel-Biet","year":"2013","unstructured":"Israel-Biet D, Valeyre D. Diagnosis of pulmonary sarcoidosis. Curr Opin Pulm Med. 2013;19:510\u20135.","journal-title":"Curr Opin Pulm Med"},{"key":"3455_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1573405614666180528101755","volume":"15","author":"M Tana","year":"2019","unstructured":"Tana M, di Carlo S, Romano M, Alessandri M, Schiavone C, Montagnani A. FDG-PET\/CT assessment of pulmonary sarcoidosis: A guide for internists. Curr Med Imaging Rev. 2019;15:21\u20135.","journal-title":"Curr Med Imaging Rev"},{"key":"3455_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1573405614666180626120832","volume":"15","author":"MT Maccarone","year":"2019","unstructured":"Maccarone MT. FDG-PET scan in sarcoidosis: clinical and imaging indications. Curr Med Imaging Rev. 2019;15:4\u20139.","journal-title":"Curr Med Imaging Rev"},{"key":"3455_CR33","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s10067-020-05022-6","volume":"39","author":"L Demaria","year":"2020","unstructured":"Demaria L, Borie R, Benali K, Piekarski E, Goossens J, Palazzo E, et al. 18F-FDG PET\/CT in bone sarcoidosis: an observational study. Clin Rheumatol. 2020;39:2727\u201334.","journal-title":"Clin Rheumatol"},{"key":"3455_CR34","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1084\/jem.178.6.2255","volume":"178","author":"M Salmi","year":"1993","unstructured":"Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med. 1993;178:2255\u201360.","journal-title":"J Exp Med"},{"key":"3455_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/ars.2017.7418","volume":"30","author":"M Salmi","year":"2019","unstructured":"Salmi M, Jalkanen S. Vascular adhesion protein-1: a cell surface amine oxidase in translation. Antioxid Redox Signal. 2019;30:314\u201332.","journal-title":"Antioxid Redox Signal"},{"key":"3455_CR36","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1172\/JCI119389","volume":"99","author":"M Salmi","year":"1997","unstructured":"Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest. 1997;99:2165\u201372.","journal-title":"J Clin Invest"},{"key":"3455_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0735-1097(00)00706-3","volume":"36","author":"K Jaakkola","year":"2000","unstructured":"Jaakkola K, Jalkanen S, Kaunism\u00e4ki K, V\u00e4nttinen E, Saukko P, Alanen K, et al. Vascular adhesion protein-1, intercellular adhesion molecule-1 and P-selectin mediate leukocyte binding to ischemic heart in humans. J Am Coll Cardiol. 2000;36:122\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"3455_CR38","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0002-9440(10)65514-9","volume":"155","author":"K Jaakkola","year":"1999","unstructured":"Jaakkola K, Kaunism\u00e4ki K, Tohka S, Yegutkin G, V\u00e4nttinen E, Havia T, et al. Human vascular adhesion protein-1 in smooth muscle cells. Am J Pathol. 1999;155:1953\u201365.","journal-title":"Am J Pathol"},{"key":"3455_CR39","doi-asserted-by":"publisher","first-page":"9515","DOI":"10.1074\/jbc.274.14.9515","volume":"274","author":"M Moldes","year":"1999","unstructured":"Moldes M, F\u00e8ve B, Pairault J. Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage. differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase. J Biol Chem. 1999;274:9515\u201323.","journal-title":"J Biol Chem"},{"key":"3455_CR40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1471-4906(01)01870-1","volume":"22","author":"M Salmi","year":"2001","unstructured":"Salmi M, Jalkanen S. VAP-1: an adhesin and an enzyme. Trends Immunol. 2001;22:211\u20136.","journal-title":"Trends Immunol"},{"key":"3455_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jneuroim.2006.05.014","volume":"177","author":"L Airas","year":"2006","unstructured":"Airas L, Mikkola J, Vainio JM, Elovaara I, Smith DJ. Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. J Neuroimmunol. 2006;177:132\u20135.","journal-title":"J Neuroimmunol"},{"key":"3455_CR42","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00702-007-0699-3","volume":"114","author":"AM O\u2019Rourke","year":"2007","unstructured":"O\u2019Rourke AM, Wang EY, Salter-Cid L, Huang L, Miller A, Podar E, et al. Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. J Neural Transm (Vienna). 2007;114:845\u20139.","journal-title":"J Neural Transm (Vienna)"},{"key":"3455_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1172\/JCI73722","volume":"125","author":"CJ Weston","year":"2015","unstructured":"Weston CJ, Shepherd EL, Claridge LC, Rantakari P, Curbishley SM, Tomlinson JW, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015;125:501\u201320.","journal-title":"J Clin Invest"},{"key":"3455_CR44","doi-asserted-by":"publisher","first-page":"901693","DOI":"10.3389\/fimmu.2022.901693","volume":"13","author":"R Viitanen","year":"2022","unstructured":"Viitanen R, Virtanen H, Liljenb\u00e4ck H, Moisio O, Li X-G, Nicolini V, et al. [68Ga]Ga-DOTA-Siglec-9 detects pharmacodynamic changes of FAP-targeted IL2 variant immunotherapy in B16-FAP melanoma mice. Front Immunol. 2022;13:901693.","journal-title":"Front Immunol"},{"key":"3455_CR45","doi-asserted-by":"publisher","first-page":"537382","DOI":"10.3389\/fimmu.2020.537382","volume":"11","author":"KM Hena","year":"2020","unstructured":"Hena KM. Sarcoidosis epidemiology: race matters. Front Immunol. 2020;11:537382.","journal-title":"Front Immunol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03455-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:26:02Z","timestamp":1781623562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-025-03455-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3455"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03455-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the joint Ethics Committee of the University of Turku and Turku University Hospital (ETMK 35\/1800\/2018), and by the Finnish Medicines Agency (EudraCT 2018-001002-29). Each subject provided informed consent before entering the study. The study was registered as a clinical trial (NCT03755245). A lung cancer patient participated in another clinical trial NCT05212103 (ETMK 101\/2021), but dropped out after the first scan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Maria Silvoniemi received speaker fees and\/or honoraria for advisory boards from MSD, BMS, Roche, Pfizer, AstraZeneca, Amgen, Novartis, and Boehringer-Ingelheim (not related to the current study). Antti Saraste has consultancy fees from AstraZeneca, Novo Nordisk, and Pfizer, and speaker fees from Abbott, AstraZeneca, BMS, Janssen, and Pfizer (not related to the current study). Sirpa Jalkanen owns patent regarding VAP-1 as a target for imaging. The remaining authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}